Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease
Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal... (Source: Virology Journal)
Source: Virology Journal - March 20, 2024 Category: Virology Authors: Marta Colaneri, Giovanni Scaglione, Federico Fassio, Lucia Galli, Alessia Lai, Annalisa Bergna, Arianna Gabrieli, Maciej Tarkowski, Carla Della Ventura, Valeria Colombo, Laura Cordier, Davide Bernasconi, Mario Corbellino, Gianfranco Dedivitiis, Silvia Bor Tags: Brief Report Source Type: research
Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan: an observational study
Conclusions
Our findings suggest that provider-level factors, such as the clinical experience of treating the patients with COVID-19, play an important role in the appropriate prescription of antiviral medications for COVID-19 in the primary care setting. (Source: BMJ Open)
Source: BMJ Open - March 15, 2024 Category: General Medicine Authors: Miyawaki, A., Kitajima, K., Iwata, A., Sato, D., Tsugawa, Y. Tags: Open access, Health services research Source Type: research
A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient
Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients. Co-packaged nirmatrelvi... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - March 15, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang and Yi-Hsi Wang Tags: Case Report Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (Paxlovid < sup > TM < /sup > ) recipients in Canada, 2022: a descriptive cohort study
CONCLUSION: In the first months of its availability in Canada, N/R was mostly used in vaccinated patients 60 years and older with one or more comorbidities. Severe outcomes in N/R recipients were uncommon and mostly reported in patients with risk factors.PMID:38481652 | PMC:PMC10936901 | DOI:10.14745/ccdr.v49i10a05 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 14, 2024 Category: Infectious Diseases Authors: Nadine Sicard Susan Squires Muhammad Mullah Peter Daley Source Type: research
Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
CONCLUSIONS: In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile.PMID:38473412 | DOI:10.3390/cancers16051055 (Source: Cancer Control)
Source: Cancer Control - March 13, 2024 Category: Cancer & Oncology Authors: Andrea J Haddad Ray Y Hachem Mohamed Moussa Ying Jiang Hiba R Dagher Patrick Chaftari Anne-Marie Chaftari Issam I Raad Source Type: research
The Impacts of Nirmatrelvir –Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic
ConclusionNirmatrelvir –ritonavir was effective in reducing myocardial injury as well as long-term adverse cardiovascular outcomes among hospitalized patients with COVID-19 amid the omicron wave of the pandemic. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 11, 2024 Category: Cardiology Source Type: research
A Global Phase II Randomized trial comparing Oral Taxane ModraDoc006/r to Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global randomized phase II trial and compared to the current standard chemotherapy regimen of intravenous (i.v.) docetaxel and prednisone. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 9, 2024 Category: Cancer & Oncology Authors: Ulka N. Vaishampayan, Marianne Keessen, Robert Dreicer, Elisabeth I. Heath, Tomas Buchler, P éter F. Árkosy, CsosziTibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V. Orlov, Alexey Plekhanov, Maria Smagina, Sergei Varlamov, Neal D. Shore Tags: Original Research Source Type: research
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.PMID:38457124 | DOI:10.1080/14787210.2024.2326561 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Behnam Amani Bahman Amani Source Type: research
